A review of the Mechanisms of Action and Side Effects of Anti-diabetic Agents

Publish Year: 1401
نوع سند: مقاله ژورنالی
زبان: English
View: 104

This Paper With 16 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_TIPS-8-3_008

تاریخ نمایه سازی: 24 آبان 1401

Abstract:

Diabetes mellitus is a lifelong disease which occurs as a result of decreased insulin activity and/or insulin secretion associated with pathological changes such as nephropathy, retinopathy, and cardiovascular complications which occur as the disease progress. This disease has a global negative impact on both an individual and healthcare systems. Though glycemic control is considered the first step in management of diabetes, improving the general health and decreasing the impact of the chronic complications also remains a target. Single drug therapy such as insulin and insulin secretagogues, biguanides, insulin sensitizers, alpha glucosidase inhibitors, incretin mimetics, amylin antagonists and sodium-glucose co-transporter-۲ (SGLT۲) inhibitors are mostly employed in the management of diabetes mellitus; however, dual drug therapies are recommended especially in type ۲ diabetes where patients can’t achieve therapeutic goals with the single drug therapy. The mode of actions of these drugs are also key factors considered in the administration of these drugs due to their diverse side effects. So, the need for proper investigation prior to prescription of anti-diabetic agents to diabetic patients with attention for side effects that may arise. This review was aimed to outline anti-diabetic drugs taking account of their mechanism of action and associated side effects as they are applied in the management of diabetes. Keywords: Anti-diabetic, Drugs, Side effects, Review. Please cite this article as: Dahiru, Muhammad Mubarak, Nadro, Margret Samuel. A review of the mechanisms of action and side effects of anti-diabetic agents. Trends in Pharmaceutical Sciences. ۲۰۲۲;۸(۳):۱۹۵-۲۱۰. doi: ۱۰.۳۰۴۷۶/TIPS.۲۰۲۲.۹۵۹۳۱.۱۱۵۳

Authors

Mubarak Dahiru

Department of Biochemistry, Modibbo Adama University, Yola, Nigeria.

Nadro Samuel

Department of Biochemistry, Modibbo Adama University, Yola, Nigeria.

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • World Health Organisation. Classification of diabetes mellitus. World Health Organization, ...
  • American Diabetes Association Professional Practice Committee. ۲. Classification and Diagnosis ...
  • American Diabetes Association. ۹. Pharmacologic Approaches to Glycemic Treatment: Standards ...
  • Edelman SV, Polonsky WH. Type ۲ Diabetes in the Real ...
  • Denise R. Lippincott’s Illustrated Reviews: Biochemistry Fifth Edition. Hong Kong: ...
  • Rodwell VW, Bender DA, Botham KM, Kennelly PJ, Weil PA. ...
  • Dimitriadis G, Mitrou P, Lambadiari V, Maratou E, Raptis SA. ...
  • Ahmad K. Insulin sources and types: a review of insulin ...
  • Lispro. Prescribing Information. Eli Lilly and Company; ۲۰۱۸. [cited ۲۰۲۲ ...
  • Sanofi-aventis U.S. LLC. Lantus S-AU: (insulin glargine [rDNA origin] injection)[prescribing ...
  • Plank J, Bodenlenz M, Sinner F, Magnes C, Görzer E, ...
  • Potocka E, Amin N, Cassidy J, Schwartz SL, Gray M, ...
  • Tahrani AA, Barnett AH, Bailey CJ. Pharmacology and therapeutic implications ...
  • Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, ...
  • Jabade V, Hucche B, Bawage S. Metformin Drug. Int J ...
  • Corcoran C, Jacobs TF. Metformin. ۲۰۲۲ May ۲. In: StatPearls ...
  • Mohammed S, Yaqub A, Sanda K, Nicholas A, Arastus W, ...
  • Ferrannini E, DeFronzo RA. Impact of glucose-lowering drugs on cardiovascular ...
  • Derosa G, Maffioli P. α-Glucosidase inhibitors and their use in ...
  • Ferrannini G, Hach T, Crowe S, Sanghvi A, Hall KD, ...
  • Juurlink DN, Gomes T, Lipscombe LL, Austin PC, Hux JE, ...
  • Liu J, Li L, Li S, Jia P, Deng K, ...
  • Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, ...
  • Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk ...
  • Gautier JF, Choukem SP, Girard J. Physiology of incretins (GIP ...
  • Raskin P, Cincotta AH. Bromocriptine-QR therapy for the management of ...
  • Sando KR, Taylor J. Bromocriptine: its place in type ۲ ...
  • Younk LM, Mikeladze M, Davis SN. Pramlintide and the treatment ...
  • Zema MJ. Colesevelam hydrochloride: evidence for its use in the ...
  • Charles ED, Neuschwander-Tetri BA, Pablo Frias J, Kundu S, Luo ...
  • Banerjee A, Lee J, Mitragotri S. Intestinal mucoadhesive devices for ...
  • نمایش کامل مراجع